REG - Imaging Biometrics - IBAI: Strategic Direction Fueling Organic Growth

Imaging BiometricsAnnouncement

16/01/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260116:nRSP1365Pa&default-theme=true

RNS Number : 1365P  Imaging Biometrics Limited  16 January 2026

Imaging Biometrics, Ltd

("IBAI" or the "Company")

 

IBAI Sets Strategic Direction Fueling Organic Growth

 

Imaging Biometrics, Ltd, (LSE: IBAI) is pleased to provide an update on its
involvement in the development of gallium maltolate as well as its strategic
priorities for 2026.

 

In early 2022, IBAI sponsored a Phase 1 clinical trial evaluating oral gallium
maltolate for the treatment of recurrent glioblastoma. While the trial remains
open as one patient continues to receive treatment, enrollment was formally
closed in November. The study authors are currently preparing the Phase 1
results for submission to a peer‑reviewed journal.

 

The directors believe it is no longer in shareholders' interests to embark on
a Phase 2 clinical trial of gallium maltolate as previously intended. The
financial and operational resources would be better employed to concentrate
upon nearer-term commercial objectives of our imaging solutions.

 

The Company continues to hold two orphan drug designations, two rare pediatric
disease designations, and an FDA Fast Track designation, all of which remain
valuable assets that preserve future optionality.

 

We also acknowledge the GABRIEL pediatric trial-Gallium Maltolate for Better
Outcomes in Relapsed/Refractory Atypical Teratoid Rhabdoid Tumor and
High‑Grade Glioma-planned at Children's Hospital of Wisconsin. Imaging
Biometrics is not formally involved in this study, but we will closely monitor
its progress for any scientific insights that may emerge. Developments from
this trial may help inform the broader landscape of research related to
gallium maltolate, and we will continue to follow it with interest.

 

Our decision reflects a disciplined commitment to focus-ensuring that we
invest where we can deliver the greatest value for patients, clinicians, and
shareholders in the near term. The imaging business is promising stronger
commercial performance, expanding clinical adoption, and increasing
recognition for its technological differentiation. Concentrating our efforts
here allows us to build on this momentum and continue scaling in a way that
strengthens the Company's financial foundation and long‑term outlook.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 

 Imaging Biometrics Ltd

 Trevor Brown/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Lucy Williams

 Tel: 020 7220 9797

About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X, @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRGDBSUBDGLU



            Copyright 2019 Regulatory News Service, all rights reserved